Journal of the American Geriatrics Society · 2022 · 13 citations · 20 references
PharmacyPharmacotherapyPharmacy PracticeClinical PharmacologyGeriatric PharmacotherapyGeriatricsAdverse Drug Event PreventionDose Adjustment In Older AdultsGeriatric Pharmaceutical CareMedication ReviewMedication UsePotentially Inappropriate MedicationsAnticholinergic DrugsElderly Medication ManagementFeasibility Study DesignInclusive Health CareMedication Adverse EffectsMedication RecommendationRecommendation ImplementationRoutine Implementation
BACKGROUND: Given associations with serious cognitive and physical adverse effects (e.g., dementia, falls), strong anticholinergics, like urinary antimuscarinics (UAMs), should be avoided in older adults. This feasibility study aimed to (1) evaluate the implementation rate of pharmacists' recommendations intended to de-escalate UAMs, (2) quantify the change in overall anticholinergic dosing exposure from these recommendations, and (3) investigate factors that predict recommendation implementation. METHODS: This was a retrospective, observational, before-and-after study. Pharmacists (n = 18) devised strategies to de-escalate UAMs in 187 participants (mean age 72.4 ± 9.4; 77.0% female; mean number of medications 12.9 ± 4.6) of 35 Programs of All-Inclusive Care for the Elderly (PACE). PACE prescribers (non-physicians and physicians) determined whether to implement recommendations. Implementation was defined as a change in the prescription records consistent with the pharmacist's recommendation at 2-, 4-, 6-, and 9-months post-recommendation. Anticholinergic dosing exposure was measured at each time point using standardized daily doses (SDD). Multivariable logistic regression was used to identify factors that predicted recommendation implementation. RESULTS: Across 9 months, recommendations were implemented in 118 out of 187 participants, yielding a 63.1% implementation rate. Of these, 77.1% (n = 91/118) implemented by month 2. Implementers' mean overall anticholinergic SDD decreased 65.4% from baseline (baseline: 2.6 [95% CI: 2.2, 3.0] to month 9: 0.9 [95% CI: 0.6,1.2], p < 0.001) whereas non-implementers demonstrated no significant change (p = 0.52). Taking <10 baseline medications (OR 2.75; 95% CI: 1.09, 7.61); baseline UAM SDD ≥2 (OR 2.20; 95% CI: 1.11, 4.44); uncomplicated recommendations (OR 3.38; 95% CI: 1.67-7.03); and baseline calcium channel blocker use (OR 2.19; 95% CI: 1.09, 4.52) predicted implementation. CONCLUSION: Our high implementation rate indicates that pharmacists' recommendations to de-escalate UAMs as a way to reduce overall anticholinergic exposure is feasible in medically complex, community-dwelling older adults. Future research should investigate whether these recommendations benefit cognitive (e.g., delirium, dementia) and/or physical functioning (e.g., falls).
20
Cumulative Use of Strong Anticholinergics and Incident Dementia
Shelly L. Gray, Melissa L. Anderson, Sascha Dublin et al. · JAMA Internal Medicine · 2015 · 1.1K citations
The cognitive impact of anticholinergics: A clinical review
PubMed Central · 2009 · 290 citations
Challenges and Enablers of Deprescribing: A General Practitioner Perspective
Nagham Ailabouni, Prasad S. Nishtala, Dee Mangin et al. · PLoS ONE · 2016 · 218 citations · Full text